BK was able to protect slices from death in the CA3 region, showing a decrease of 0.64-fold (p < 0.0001) (Figure 5F), thus reinforcing the data obtained with the in vivo treatment of AD transgenic mice with the B2R agonist. This evidence concerns the gene BDKRB2 and Alzheimer disease.